Methods: Sputum from 72 treatment-naïve asthma patients (phenotyped as eosinophilic, neutrophilic, mixed granulocytic, paucigranulocytic) and 30 healthy controls was analyzed using 16S rRNA sequencing and untargeted metabolomics (UHPLC-MS/MS). Analyses included microbial diversity, differential taxa/metabolites, and microbiome-metabolome correlations. Diagnostic potential was assessed via Random Forest and ROC analysis.
方法:使用16 S rRNA测序和非靶向代谢组学(UHPLC-MS/MS)分析了72例未经治疗的哮喘患者(表型为嗜酸性粒细胞、嗜中性粒细胞、混合粒细胞、少粒细胞)和30例健康对照的痰液。分析包括微生物多样性,差异类群/代谢物,和微生物组代谢组的相关性。通过随机森林和ROC分析评估诊断潜力。
Results: Beta-diversity differed between asthma and controls (PERMANOVA p=0.003). Asthmatics showed depletion of Bifidobacterium and enrichment of Capnocytophaga, Neisseria, and Haemophilus. Bifidobacterium demonstrated high diagnostic accuracy (AUC=0.88). Phenotype-specific beta-diversity differences were observed (R²=0.037, p=0.043), identifying nine discriminatory genera. Akkermansia correlated positively with FEV1%pred (r=0.32, p=0.008). Metabolomics identified 489 differential metabolites (56.85% lipids), with efferocytosis pathway enrichment and upregulation of sphingosine-1-phosphate (S1P) and lysophosphatidylcholine (LysoPC). Bifidobacterium depletion correlated with elevated S1P (r=-0.41, p<0.001).
结果:哮喘和对照组之间的β多样性不同(PERMANOVA p=0.003)。哮喘患者双歧杆菌减少,二氧化碳噬纤维菌、奈瑟氏菌和嗜血杆菌增多。双歧杆菌表现出较高的诊断准确性(AUC=0.88)。观察到表型特异性β多样性差异(R²=0.037,p=0.043),确定了9个歧视性属。Akkermansia与FEV1%pred呈正相关(r=0.32,p=0.008)。代谢组学鉴定了489种差异代谢物(56.85%脂质),具有胞浆细胞增多途径富集和1-磷酸鞘氨醇(S1 P)和溶血磷脂酰胆碱(LysoPC)上调。双歧杆菌耗竭与S1 P升高相关(r=-0.41,p 0.001)。
Conclusion: This integrated multi-omics study reveals distinct microbiome-metabolome signatures across asthma phenotypes, linking microbial dysbiosis to pro-inflammatory lipid accumulation and lung function. Findings offer potential biomarkers for phenotype-specific diagnosis and targeted interventions.
结论:这项综合性多组学研究揭示了哮喘表型中不同的微生物组-代谢组特征,将微生物生态失调与促炎脂质积累和肺功能联系起来。这些发现为表型特异性诊断和靶向干预提供了潜在的生物标志物。